UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 119

Sortiert nach

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Clinical cancer research, 2020-01, Vol.26 (1), p.242-255

2020

Link zum Volltext

Verfügbarkeit prüfen

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation

Journal of cell science, 2014-02, Vol.127 (Pt 4), p.788

2014

Link zum Volltext

Verfügbarkeit prüfen

NRG1 fusions in breast cancer

Breast cancer research : BCR, 2021-01, Vol.23 (1), p.3-12, Article 3

2021

Link zum Volltext

Verfügbarkeit prüfen

Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone

Cancer research (Chicago, Ill.), 2015-01, Vol.75 (1), p.194-202

2015

Link zum Volltext

Verfügbarkeit prüfen

Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes

BMC genomics, 2012-12, Vol.13 (1), p.719-719, Article 719

2012

Link zum Volltext

Verfügbarkeit prüfen

The relative timing of mutations in a breast cancer genome

PloS one, 2013-06, Vol.8 (6), p.e64991-e64991

2013

Link zum Volltext

Verfügbarkeit prüfen

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

Nature communications, 2019-05, Vol.10 (1), p.1-22, Article 2030

2019

Link zum Volltext

Verfügbarkeit prüfen

Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes

The Journal of pathology, 2012-08, Vol.227 (4), p.446-455

2012

Link zum Volltext

Verfügbarkeit prüfen

Are breast cancers driven by fusion genes?

Breast cancer research : BCR, 2012-03, Vol.14 (2), p.303-303, Article 303

2012

Link zum Volltext

Verfügbarkeit prüfen

Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer

Frontiers in oncology, 2022-03, Vol.12, p.856132-856132

2022

Link zum Volltext

Verfügbarkeit prüfen

Large duplications at reciprocal translocation breakpoints that might be the counterpart of large deletions and could arise from stalled replication bubbles

Genome research, 2011-04, Vol.21 (4), p.525

2011

Link zum Volltext

Verfügbarkeit prüfen

Single-molecule analysis of genome rearrangements in cancer

Nucleic acids research, 2011-07, Vol.39 (13), p.e85

2011

Link zum Volltext

Verfügbarkeit prüfen

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer

Annals of oncology, 2018-01, Vol.29 (1), p.145-153

2018

Link zum Volltext

Verfügbarkeit prüfen

Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer

British journal of cancer, 2024-03, Vol.130 (4), p.682-693

2024

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Journal of clinical oncology, 2022-08, Vol.40 (22), p.2408-2419

2022

Link zum Volltext

Verfügbarkeit prüfen

Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma

British journal of cancer, 2022-05, Vol.126 (8), p.1186-1195

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 553: Personalized circulating tumor DNA analysis in head and neck squamous cell carcinoma: Preliminary results of the Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and NeckSquamous Cell Carcinoma (LIONESS) study

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.553-553

2021

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.383-391

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3097: Analytical development of the RaDaRTM assay, a highly sensitive and specific assay for the monitoring of minimal residual disease

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3097-3097

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 598: Resistance mechanisms to BRAF inhibition identified by single circulating tumor cell and cell-free tumor DNA molecular profiling in BRAF -mutant non-small cell lung cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.598-598

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 536: Molecular residual disease detection in early stage breast cancer with a personalized sequencing approach

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.536-536

2021

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF -Mutant Metastatic Non-Small Cell Lung Cancer

Clinical cancer research, 2020-12, Vol.26 (23), p.6242-6253

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(105)

Publikationsform

Sprache

Englisch
(119)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA

Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling

NRG1 fusions in breast cancer

Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone

Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

The relative timing of mutations in a breast cancer genome

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes

Are breast cancers driven by fusion genes?

Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer

Large duplications at reciprocal translocation breakpoints that might be the counterpart of large deletions and could arise from stalled replication bubbles

Single-molecule analysis of genome rearrangements in cancer

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer

Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma

Abstract 553: Personalized circulating tumor DNA analysis in head and neck squamous cell carcinoma: Preliminary results of the Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and NeckSquamous Cell Carcinoma (LIONESS) study

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression

Abstract 3097: Analytical development of the RaDaRTM assay, a highly sensitive and specific assay for the monitoring of minimal residual disease

Abstract 598: Resistance mechanisms to BRAF inhibition identified by single circulating tumor cell and cell-free tumor DNA molecular profiling in BRAF -mutant non-small cell lung cancer

Abstract 536: Molecular residual disease detection in early stage breast cancer with a personalized sequencing approach

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF -Mutant Metastatic Non-Small Cell Lung Cancer

Suchergebnisse filtern